Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Fáze IIB, randomizovaná, dvojitě zaslepená, placebem kontrolovaná studie Elismemetrep (K-304) při léčbě migrény

30. října 2026 aktualizováno: TriGemX Bio, Inc.

Fáze IIB, randomizovaná, dvojitě zaslepená, placebem kontrolovaná studie Elismemetrep (K-304) při léčbě migrény: bude vyhodnocena řada dávek

This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.

Přehled studie

Postavení

Dokončeno

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Aktuální)

431

Fáze

  • Fáze 2

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • Alabama
      • Birmingham, Alabama, Spojené státy, 35205
        • Central Research Associates, LLC (CRA) dba Flourish Research
      • Mobile, Alabama, Spojené státy, 36608
        • AMR Mobile
    • Arizona
      • Tucson, Arizona, Spojené státy, 85710
        • Wake Research/ Tucson Neuroscience Research
    • California
      • Canoga Park, California, Spojené státy, 91303
        • Hope Clinical Research
      • Encino, California, Spojené státy, 91316
        • WR-PRI, LLC (Encino)
      • Huntington Beach, California, Spojené státy, 92647
        • Marvel Clinical Research
      • La Mesa, California, Spojené státy, 91942
        • Eximia Research - CA
      • Lemon Grove, California, Spojené státy, 91945
        • Synergy San Diego
      • Newport Beach, California, Spojené státy, 92660
        • WR-PRI, LLC (Newport Beach)
      • Oceanside, California, Spojené státy, 92056
        • Excell Research, Inc.
      • Pomona, California, Spojené státy, 91767
        • Empire Clinical Research
      • Riverside, California, Spojené státy, 92503
        • Artemis Institute for Clinical Research - Riverside
      • San Diego, California, Spojené státy, 89109
        • Acclaim Clinical Research
      • San Diego, California, Spojené státy, 92103
        • Artemis Institute for Clinical Research - San Diego
      • Walnut Creek, California, Spojené státy, 94598
        • Diablo Clinical Research, Inc.
      • West Hills, California, Spojené státy, 91307
        • Focus Clinical Research
    • Connecticut
      • Cromwell, Connecticut, Spojené státy, 06416
        • CT Clinical Research
    • Georgia
      • Atlanta, Georgia, Spojené státy, 30329
        • DelRicht Research
      • Stockbridge, Georgia, Spojené státy, 30281
        • Clinical Research Atlanta - Stockbridge
    • Idaho
      • Boise, Idaho, Spojené státy, 83704
        • Northwest Clinical Trials
    • Illinois
      • Chicago, Illinois, Spojené státy, 60607
        • Cedar Crosse Research Center
      • Flossmoor, Illinois, Spojené státy, 60422
        • Healthcare Research Network II, LLC
    • Kansas
      • Overland Park, Kansas, Spojené státy, 66202
        • Collective Medical Research
      • Wichita, Kansas, Spojené státy, 67207
        • Alliance for Multispecialty Research
    • Kentucky
      • Louisville, Kentucky, Spojené státy, 40213
        • L-MARC Research Center
    • Louisiana
      • Chalmette, Louisiana, Spojené státy, 70043
        • Crescent City Headache & Neurology Center
      • New Orleans, Louisiana, Spojené státy, 70115
        • DelRicht Research
    • Michigan
      • Ann Arbor, Michigan, Spojené státy, 48104
        • Michigan Head Pain and Neurological Institute
    • Minnesota
      • Minneapolis, Minnesota, Spojené státy, 55402
        • Clinical Research Institute
    • Mississippi
      • Gulfport, Mississippi, Spojené státy, 39503
        • DelRicht Research
    • Missouri
      • Hazelwood, Missouri, Spojené státy, 63042
        • Healthcare Research Network
    • Nevada
      • Las Vegas, Nevada, Spojené státy, 89109
        • Excel Clinical Research
      • North Las Vegas, Nevada, Spojené státy, 89119
        • Las Vegas Clinical Trials
    • New Mexico
      • Albuquerque, New Mexico, Spojené státy, 87102
        • Albuquerque Clinical Trials, Inc.
    • New York
      • Amherst, New York, Spojené státy, 14226
        • Dent Neurosciences Research Center
      • Manlius, New York, Spojené státy, 13104
        • CNY Clinical Research
      • Rochester, New York, Spojené státy, 14609
        • Rochester Clinical Research
      • Williamsville, New York, Spojené státy, 14221
        • Upstate Clinical Research Associates LLC
    • North Carolina
      • Greensboro, North Carolina, Spojené státy, 27405
        • Headache Wellness Center
      • High Point, North Carolina, Spojené státy, 27260
        • Peters Medical Research
    • Ohio
      • Cincinnati, Ohio, Spojené státy, 45212
        • CTI Clinical Research Center
    • Oklahoma
      • Edmond, Oklahoma, Spojené státy, 73034
        • OK Clinical Research, LLC
      • Oklahoma City, Oklahoma, Spojené státy, 73102
        • Hightower Clinical
      • Tulsa, Oklahoma, Spojené státy, 74133
        • DelRicht Research
      • Yukon, Oklahoma, Spojené státy, 73099
        • Tekton Research
    • Oregon
      • Portland, Oregon, Spojené státy, 97210
        • Summit Research Network
    • Pennsylvania
      • Allentown, Pennsylvania, Spojené státy, 18103
        • Lehigh Center for Clinical Research
      • Philadelphia, Pennsylvania, Spojené státy, 19114
        • Clinical Research Philadelphia, LLC
      • Scottdale, Pennsylvania, Spojené státy, 15683
        • Frontier Clinical Research, LLC
      • Smithfield, Pennsylvania, Spojené státy, 15478
        • Frontier Clinical Research, LLC
      • West Chester, Pennsylvania, Spojené státy, 19380
        • Atlas-Clinical
    • South Carolina
      • Charleston, South Carolina, Spojené státy, 29406
        • Clinical Trials of South Carolina
      • North Charleston, South Carolina, Spojené státy, 29405
        • Coastal Carolina Research Center
    • Tennessee
      • Chattanooga, Tennessee, Spojené státy, 37421
        • WR-ClinSearch
      • Knoxville, Tennessee, Spojené státy, 37909
        • AMR Knoxville (Formerly NOCCR)
      • Nashville, Tennessee, Spojené státy, 37203
        • Clinical Research Associates, Inc.
    • Texas
      • Austin, Texas, Spojené státy, 78745
        • Tekton Research
      • Austin, Texas, Spojené státy, 78737
        • Donald J Garcia Jr, MD, PA
      • Dallas, Texas, Spojené státy, 75251
        • FutureSearch Trials of Dallas, LP
      • Houston, Texas, Spojené státy, 77024
        • Victorium Clinical Research LTD CO
      • Splendora, Texas, Spojené státy, 77372
        • APD Clinical Research
      • Waxahachie, Texas, Spojené státy, 75165
        • ClinPoint Trials
    • Utah
      • Ogden, Utah, Spojené státy, 84405
        • Advanced Research Institute
    • Virginia
      • Newport News, Virginia, Spojené státy, 23606
        • Health Research of Hampton Roads, Inc.
    • West Virginia
      • Morgantown, West Virginia, Spojené státy, 26505
        • Frontier Clinical Research, LLC
    • Wisconsin
      • Kenosha, Wisconsin, Spojené státy, 53144
        • Clinical Investigation Specialist

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 70 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  1. Be a male or female, age 18 to 70 years, inclusive, at the time of signing informed consent.

  2. Participant has greater than a one-year history of migraine with or without aura as defined by International Conference on Harmonization (IHS) criteria 1.1 and 1.2 and his/her migraines typically last between 4 to 72 hours, if untreated as documented in the participant's medical records from his/her treating physician and confirmed by the investigator.

  3. Participant has had ≥2 and ≤10 moderate or severe migraine attacks per month in each of the two months prior to screening (Visit 1).

  4. Meet the following requirements:

    1. Is a male OR

    2. Is a female who is of non-childbearing potential defined by at least 1 of the following criteria:

    3. Postmenopausal (aged >45 years and with a minimum of 12 months of spontaneous amenorrhea with a screening serum follicle-stimulating hormone (FSH) level in the menopausal range established for the central laboratory.

    4. Post hysterectomy, bilateral oophorectomy or bilateral salpingectomy, based on the participant's recall of their medical history.

      OR

    5. Is a female of reproductive potential and:

    6. agrees to remain abstinent from heterosexual activity*

      *Abstinence can be used as the sole method of contraception if it is in line with the participant's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ethics committees. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.

    7. or agrees to use (or have their partner use) a birth control method that is acceptable from the first dose of study drug until the end of trial (EoT) visit. Acceptable methods of birth control are:

      • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:

        • oral
        • intravaginal
        • transdermal
      • progestogen-only hormonal contraception associated with inhibition of ovulation:

        • oral
        • injectable
        • implantable
      • intrauterine device (IUD)

      • intrauterine hormone-releasing system (IUS)

      • bilateral tubal occlusion

      • vasectomised partner

      • sexual abstinence

      • progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action

      • male or female condom with or without spermicide

      • cap, diaphragm or sponge with spermicide

      • A combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods)

    This condition is waived if the participant is proven to have no child-bearing potential (eg, hysterectomy).

  5. Participant voluntarily agrees to participate in the study by giving written informed consent.

  6. Participant is able to read, understand and complete the study questionnaires and diary.

  7. Be willing and able to comply with the study schedule of visits, all trial procedures and restrictions.

  8. Be willing to use their own personal, qualified smartphone to download study specific eDiary applications for use during the study.

Exclusion Criteria:

  1. Is a female who is pregnant, breast-feeding or intends to become pregnant during the planned course of the study. Note: Participants must have a negative serum pregnancy test (β-human chorionic gonadotropin (β-hCG)) performed by the central laboratory prior to enrollment in the study and negative urine pregnancy result at the randomization visit.

    Migraine history related

  2. Participant has difficulty distinguishing his/her migraine attacks from tension-type headaches.

  3. Participant has a history of predominantly mild migraine attacks or migraines that usually resolve spontaneously in less than two hours.

  4. Participant has more than 15 headache-days per month or has taken medication for acute headache on more than 10 days per month in any of the three months prior to screening (Visit 1).

  5. Participant has brainstem (a.k.a. basilar-type) or hemiplegic migraine headache, or retinal migraine.

  6. Participant was >50 years old at age of first migraine onset.

  7. Participant is taking migraine prophylactic medication where the prescribed daily dose has changed during the 3 months prior to screening (Visit 1) or anticipates any change during the study. Any withdrawal of preventive medications for the treatment of migraine should be completed at least 30 days prior to screening.

    Medical history related

  8. Participant has, in the opinion of the investigator, other confounding pain syndromes, psychiatric conditions such as uncontrolled major depression, history of psychosis, dementia or significant neurological disorders other than migraine [participants who are currently being treated with non-prohibited medication for depression and symptoms are well controlled, in the opinion of the investigator, are eligible to participate in this study].

  9. Participant is at imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicidality Severity Rating Scale (C-SSRS), or of harm to others in the opinion of the investigator. Participants must be excluded if they report suicidal ideation with intent, with or without a plan (i.e., Type 4 or 5 on the C-SSRS) in the past 2 months or suicidal behavior in the past 6 months.

  10. Has a recent history (within the past 3 years of the Screening Visit) or current diagnosis or evidence of endocrine, hematological, immunological, renal, respiratory, neurologic, gastrointestinal, biliary, or genitourinary abnormalities or diseases that, per the investigator's judgement, may jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results.

  11. Has a history of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed if they have received treatment and follow-up consistent with local standard of care.

  12. Participant history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Participants with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or transient ischemic attack (TIA) during the 6 months prior to screening.

  13. Has a history of human immunodeficiency virus disease.

  14. Participant has a history of gastric or small intestinal surgery (including gastric bypass surgery or banding but not including cholecystectomy or appendectomy) or has a disease that causes malabsorption.

    Laboratory, vital sign, and electrocardiogram (ECG) related

  15. Has a positive test result at screening for hepatitis B surface antigen (Ag), hepatitis C virus antibody.

  16. Has a screening estimated Glomerular Filtration Rate (eGFR) estimated with the Modification of Diet in Renal Disease (MDRD) equation of <45 ml/min/1.73 m^2.

  17. Has a screening result for alanine aminotransferase or aspartate aminotransferase (ALT or AST) of >2.0X upper limit of normal (ULN) or total bilirubin >1.5X ULN at the Screening Visit. Note: An isolated bilirubin >1.5X ULN is acceptable if bilirubin is fractionated, and direct bilirubin is within the laboratory normal range.

  18. Has a corrected QT interval to Fridericia's formula (QTcF) >450 milliseconds (msec) for males and >470 msec for females at screening.

  19. Has a mean value for triplicate seated systolic blood pressure >160 mmHg and/or diastolic blood pressure (BP) >95 mmHg measured after at least 5 minutes at rest at the Screening Visit.

    Note: If a participant's BP is exclusionary on the first triplicate assessment at the Screening Visit, they may have 1 repeat triplicate BP assessment at that visit after another rest of at least 10 minutes.

    Medication use and substance abuse related

  20. Has known history of or suspected abuse of alcohol or recreational drugs at screening.

  21. Has use of soft drugs (such as marijuana or any substances containing tetrahydrocannabinol (THC) or cannabidiol (CBD)) within 3 months prior to screening, or hard drugs (such as cocaine, illicit narcotics/opiates) within 6 months prior to screening.

  22. Has a positive drug screen at screening. Note: If benzodiazepines are detected on the drug screen, this is not exclusionary if they are prescribed a benzodiazepine for a therapeutic purpose (e.g. for insomnia) and confirmatory documentation is obtained from the prescribing physician.

  23. Is currently in violation of study requirements for prohibited and permissible concomitant medications (not already specified in other criteria) or is anticipated to violate these requirements during study participation.

  24. Has any use of prescription opiate medications within 14 days of screening or any anticipated/potential use of opiates during study participation.

  25. History of use of ergotamine medications on greater than/equal 10 days per month on a regular basis for greater than/equal 3 months prior to screening.

  26. History of non-narcotic analgesic intake on greater than/equal 15 days per month for greater than/equal 3 months prior to screening.

    Other

  27. Has known or suspected hypersensitivity to trial product(s) or related products.

  28. Has a history of multiple significant and/or any severe allergies (e.g., food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food.

  29. Has any surgery scheduled for the duration of the trial.

  30. Had major surgery or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the Screening Visit; has a screening hemoglobin <11.0 g/dL (males) or <10.0 g/dL (females), or has a known hemoglobinopathy (e.g. sickle cell anemia, hemolytic anemia).

  31. Has previous participation in this trial. Participation is defined as signed informed consent.

  32. Has participated in any clinical trial of an approved or non-approved investigational biological medicinal product (e.g. antibody therapy) within 90 days of screening or has participated in any clinical trial of an approved or non-approved investigational small molecule medicinal product within 30 days or 5 half-lives (whichever is longer) of screening.

  33. Has any other disorder, unwillingness or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results.

  34. Is an employee or immediate family member (e.g., spouse, parent, child, sibling) of the Sponsor or study site.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Trojnásobný

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Elismetrep (K-304) Dose Level 1

Participants received a single dose of elismetrep 2 mg

Administered orally

Experimentální: Elismetrep (K-304) Dose Level 2

Participants received a single dose of elismetrep 5 mg

Administered orally

Experimentální: Elismetrep (K-304) Dose Level 3

Participants received a single dose of elismetrep 10 mg

Administered orally

Experimentální: Elismetrep (K-304) Dose Level 4

Participants received a single dose of elismetrep 20 mg

Administered orally

Komparátor placeba: Placebo

Participants received a single dose of elismetrep-matched placebo

Administered orally

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Pain Freedom
Časové okno: 2 hours post-dose

Assessed using the number of evaluable participants that reported no pain at 2 hours post-dose. Pain was measured on a 4-point Likert scale (0 = none, 1 = mild, 2 = moderate, 3 = severe)

2 hours post-dose

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Proportion of Participants Who Experienced 1 or More Treatment-emergent Adverse Events (AEs)
Časové okno: up to 7 days after administration of study therapy
up to 7 days after administration of study therapy
Freedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia or Photophobia)
Časové okno: 2 hours post-dose

Assessed using the number of evaluable participants that reported the absence of their MBS

2 hours post-dose
Pain Relief
Časové okno: 2 hours post-dose

Assessed using the number of evaluable participants that reported a pain level of moderate or severe (responses of 2 or 3 on the 4-point Likert scale) at baseline and then reported a pain level of none or mild (response of 0 or 1).

2 hours post-dose
Freedom From Photophobia
Časové okno: 2 hours post-dose

Assessed by tabulating the number of participants that reported the absence of photophobia at 2 hours post-dose in the subset of participants that reported the presence of photophobia at baseline.

2 hours post-dose
Freedom From Phonophobia
Časové okno: 2 hours post-dose

Assessed by tabulating the number of participants that reported the absence of phonophobia at 2 hours post-dose in the subset of participants that reported the presence of phonophobia at baseline.

2 hours post-dose
Freedom From Nausea
Časové okno: 2 hours post-dose

Assessed by tabulating the number of participants that reported the absence of nausea at 2 hours post-dose in the subset of participants that reported the presence of nausea at baseline.

2 hours post-dose
The Probability of Requiring Rescue Medication
Časové okno: 24 hours post-dose

Assessed using the number of participants that took rescue medication within 24 hours after administration of study therapy

24 hours post-dose
Sustained Pain Freedom
Časové okno: From 2 to 24 hours

Assessed using the number of participants that did not experience any headache pain through the time period of interest

From 2 to 24 hours
Sustained Pain Relief
Časové okno: From 2 to 24 hours

Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest.

From 2 to 24 hours
Sustained Pain Freedom
Časové okno: From 2 to 48 hours

Assessed using the number of participants that did not experience any headache pain through the time period of interest.

From 2 to 48 hours
Sustained Pain Relief
Časové okno: From 2 to 48 hours

Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest.

From 2 to 48 hours
Proportion of Participants Who Experienced 1 or More Treatment-emergent Serious Adverse Events (SAEs)
Časové okno: Up to 7 days after administration of study therapy

Serious adverse events were assessed in the Safety Analysis Set.

Up to 7 days after administration of study therapy

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

11. března 2025

Primární dokončení (Aktuální)

4. srpna 2025

Dokončení studie (Aktuální)

4. srpna 2025

Termíny zápisu do studia

První předloženo

21. února 2025

První předloženo, které splnilo kritéria kontroly kvality

25. února 2025

První zveřejněno (Aktuální)

26. února 2025

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

16. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

30. října 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • K-304 P001

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .